A novel PARP1-targeted Auger radiotherapeutic shows translational potential as a theranostic tool for imaging and killing cancer cells, resulting in tumor delineation and prolonged survival in a glioblastoma model.
Introduction
Glioblastoma multiforme (GBM) is one of the deadliest forms of solid tumors, with a 5-year survival rate as low as 5% (1). Clinical intervention typically consists of maximal safe surgical resection followed by adjuvant chemo-radiotherapy. This therapeutic regimen, unfortunately, imparts only limited improvements to survival (2) . Additionally, the GBM molecular heterogeneity represents a robust challenge in need of better imaging tools that would allow for the monitoring of therapy response and lead to better and more personalized therapeutic plans. Furthermore, the presence of the blood-brain barrier (BBB) biochemically limits the pharmacokinetics of many GBM drug candidates.
A novel approach for treating GBM is therefore urgently needed, one that would address both pharmacodynamic as well as pharmacokinetic hurdles (3, 4) . Promising delivery strategies to overcome these problems in the clinics include convection enhanced delivery (CED) (5, 6) and intrathecal injection (7, 8) .
A known molecular biomarker for most tumors, including GBM, is poly(ADP-ribose) Polymerase 1 (PARP-1) (9) (10) (11) (12) (13) (14) (15) . PARP-1 is recruited to the nucleus of cancer cells and binds DNA as a single-strand break (SSB) repair enzyme (16) . This central role has been successfully leveraged for the development of various PARP inhibitors, both as a monotherapy and in combination with other therapeutics (17, 18) . Modified PARP inhibitors have also been widely used for tumor detection and imaging due to their cancer specificity and their high target-to-background contrast (14, 15, (19) (20) (21) (22) (23) (24) (25) ; more recently, they have found theranostic applications (26) .
Here, we focus on a less used type of radioactive emission: Auger radiation. Auger emitters are an extremely potent radioactive source for targeted radiotherapy, characterized by their greater linear energy transfer, incredibly short range, and ability to cause a complex, lethal DNA damage as compared to traditional X-rays or b-particles (27) (28) (29) (30) . Previous attempts to use Auger emitters as cancer therapies have not been successful, due to the limited range of the radiation emitted and the difficulty of reliably delivering the lethal electrons close enough to the DNA target (< 100 Å) (31) (32) (33) .
In this study, we developed and characterized 123 I-MAPi, the first Auger-based theranostic PARP inhibitor able to directly deliver its lethal payload within a 50-angstrom distance of the DNA of GBM cancer cells ( fig. 1A ). This distance is within the Auger radius of action, resulting in an effective preclinical cancer treatment drug and leading to improved survival in a preclinical GBM model. We used the 159 keV gamma ray to image tumor progression and calculate dosimetry and treatment efficacy using SPECT imaging.
Taken together, these results illustrate the tremendous potential of 123 I-MAPi as an Augeremitting PARP inhibitor and a theranostic agent for GBM treatment.
RESULTS

Synthesis of 123 I-MAPi and in vitro validation
We previously showed that it is possible to successfully conjugate a PARP inhibitor with radioiodine without altering the high affinity to the target with an IC50 in the nanomolar range (11 ± 3 nM) and a logPCHI of 2.3 (34) . 123 I-MAPi is a novel, previously unreported isotopologue, and was synthesized with a final molar activity of 3.93 ± 0.10 GBq/μmol.
Radiochemical purity was 99.1 ± 0.9% for all prepared compounds ( fig. 1B ).
Pharmacological properties determined with 127 I-PARPi suggest that 123 I-MAPi ( fig. 1B, S1B ), retains the same properties as 131 I-PARPi, which have been shown to be similar to the FDAapproved PARP inhibitor Olaparib (26, 34) .
In vitro internalization was tested on U251 cells expressing PARP1 ( fig. 1D, S1A ). 123 I-MAPi (37 kBq/well) was added to adherent cells in monolayer and uptake was calculated by measuring gamma radiation in cell lysates at different time points. We confirmed rapid cellular internalization, with 50% of the final total uptake being reached after 5 -10 minutes postincubation and with an uptake plateau reached at 1 h post-treatment. The final total uptake was ~8% of added activity, Vmax = 8.2 ± 0.2 % compared to blocked uptake, Vmax = 3.8 ± 0.1 % (Michaelis-Menten fit, R 2 = 0.974 and R 2 = 0.879, respectively). Uptake was blocked with a 100-fold excess dose of Olaparib to show target specificity. Na-123 I was used as a control and showed significantly lower uptake, Vmax = 2.5 ± 0. fig. 2A, fig. S2A ). Biodistribution at 18 h was also examined and showed higher tumor uptake (33.4 ± 28.0 % ID/g) compared to the tumor of blocked animals (0.4 ± 0.1 % ID/g) ( fig. 2B ). Tumor-to-muscle ratios in 123 I-MAPi treated mice versus blocked mice were > 500 and 5, respectively, with less than 1% ID/g in all clearing organs.
Auger particles are highly cytotoxic when they can directly interact with the DNA and cause complex damage. However, they are significantly less so in the cellular cytosol, where they are beyond the reach of their DNA target (27) . As liver clearance is the main route of excretion of 123 I-MAPi that could cause dose-limiting problems in the clinic, we investigated potential clinical liver failure by observing specific liver toxicity in our preclinical study. We compared tumor and liver accumulation of PARPi-FL, a thoroughly characterized fluorescent analogue of the same PARP1 inhibitor (14, 15, 20, 34, 35) . PARPi-FL was injected intravenously (50 μg per mouse) 2 h before collecting the animals' tumor and liver ( fig. 2C and fig. S3A ). Organs were then sectioned, and tissue sections digitalized. Hoechst (150 μL/mouse of 10 mg/mL) was used for nuclear counterstaining. PARPi-FL accumulated in the nucleus of GBM cells as confirmed by co-localization with Hoechst signal. Livers were collected and imaged with an inverted confocal microscope. PARPi-FL accumulation was observed in the cytoplasm of liver cells ( fig. 2D ), suggesting that liver cells are protected from Auger-toxicity during hepatobiliary clearance, due to the large distance of the Auger emitter from the DNA ( fig. S3B ).
Imaging of an orthotopic GBM model using 123 I-MAPi
To test 123 I-MAPi in a more realistic model of GBM, we orthotopically implanted TS543 cells into the right brain hemisphere. This GBM model proved to be very consistent in growth and take rate, as we monitored by MRI imaging of the head. 50,000 cells were injected at Week 0, which resulted in rapid disease progression leading to animal death at Week 7 ( fig. 3A ).
Based on this data we decided to deliver 123 I-MAPi treatment at Week 3. 
Therapeutic efficacy of 123 I-MAPi in a GBM mouse model
We monitored the clinical potential utility of 123 I-MAPi in treating GBM in the above described orthotopic mouse model. 
Improved delivery of 123 I-MAPi for clinical translation
In clinics, to improve biodistribution toward a more effective targeted therapy, the radiopharmaceutical can be administered directly into the tumor compartment. and table 2).
Intrathecal injection of 123 I-MAPi for a further simplified clinical translation
We then investigated a more broadly used and technically feasible brain drug delivery method S5A ). Imaging confirmed favorable pharmacokinetics and specific tumor uptake, suggesting intrathecal delivery as a feasible technique for our small molecule. Unfortunately, this technique lead to surgery-related high levels of stress in the mice model preventing us from being able to monitor survival.
Discussion
In the present work, we show the results for the first preclinical characterization of an Augeremitting theranostic PARP inhibitor. We present a functioning workflow for the synthesis of a stable 123 I-MAPi compound which proved to be effective in vitro at reducing the viability of GBM cell lines. The lethality of 123 I-MAPi suggests that the DNA is in range of the Auger electrons when it is complexed with PARP1. It was further established that GBM cell death is induced through radiogenic damage rather than PARP inhibition at these tracer levels.
In vivo studies with human tumor xenografts models also show capability with a newly developed theranostic agent, 123 I-MAPi. We have shown that it can access the brain when injected intrathecally and using the intratumoral osmotic pump delivery system. While the favorable pharmacokinetics was accompanied by stressful side-effects in some mice (on account of the comparatively small volumes of the murine skull), this has not been, nor is it expected to be, a limiting factor for human studies.
To conclude, we characterized the first Auger-emitting PARP inhibitor in vivo which presented promising therapeutic results in a pre-clinical glioma model. The physical properties of Auger emission, paired with the biological distribution of a PARP inhibitor, make it possible to speculate that a dose escalation in patients could achieve high tumoricidal doses with limited normal tissue toxicity. The 159 keV gamma ray emitted is at the sweet spot for gamma camera imaging in patients and will allow for monitoring of treatment delivery across the BBB, redistribution, and precise dose evaluation, leading to truly personalized treatment plans ( fig.   S5B ). 123 I-MAPi has the potential to be a new and potent clinical agent for the treatment of brain tumors when used in conjunction with new intrathecal/CED administration methods.
Materials and Methods
General
Sodium [ 123 I]iodide in 0.1 N NaOH with a specific activity of 7.14 x10 7 GBq/g was purchased from Nordion (Ottawa, Canada). 4-(4-fluoro-3-(4-(3-iodobenzoyl)piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one was synthesized as described previously (39) . Olaparib (AZD2281) was purchased from LC Laboratories (Woburn, MA). PARPi-FL was synthesized as previously described (14, 40) . Water (>18. 
Cell Culture
The human glioblastoma cell line U251 was kindly provided by the laboratory of Dr. Blasberg 
Internalization assay
Uptake of 123 I-MAPi was tested in vitro (3 replicates). 5×10 5 U251 cells were plated 24h prior to the experiment (n = 3). Media was changed and 1 h later 3.7 kBq of 123 I-MAPi were added to the cells. For blocking, cells were incubated with a 100-fold molar excess of Olaparib 1 h before adding 123 I-MAPi. Media was removed, and cells were washed with PBS and lysed (1 M NaOH) at different time points. The lysate was collected, and uptake was determined by radioactivity on a gamma counter.
Viability assay
U251 GBM cells were incubated with 0 -296 kBq of 123 I-MAPi or equivalent dose of Olaparib overnight and then washed and incubated for 4 d in normal media (3 replicates, n = 3 each).
Viability was determined by AlamarBlue assay as indicated by the manufacturer.
Colony formation assay
Colony formation assay (CFA) was performed using U251 cells as previously described (41) (n = 3). Colony formation was measured at two weeks post 123 I-MAPi treatment and compared to 123 I-NaI. Cells were treated adding 0 -296 kBq of compound in each well. Colony count was normalized on plating efficiency at 0 kBq for each treatment.
Animal Work
Female athymic nude CrTac:NCr-Fo mice were purchased from Taconic Laboratories (Hudson, NY) at age 6-8 weeks. During subcutaneous injections, mice were anesthetized using 2% isoflurane gas in 2 L/min medical air. For intravenous injections, the lateral tail vein was used. Mice were warmed with a heat lamp, placed in a restrainer, and the tail was sterilized with alcohol pads before injection. SPECT/CT data was collected for 60 min.
Ex-vivo biodistribution and dosimetry
Biodistribution studies were performed in subcutaneous TS543 xenograft-bearing mice. Mice were randomized and divided in two groups (blocked and unblocked, ntotal = 6) and 
Intrathecal injection
Brain-tumor-bearing mice were anesthetized and injected in the intrathecal space (injection site from L3/5 or L4/5 to prevent spinal cord injury) 2.0 MBq of 123 I-MAPi in 50 μL 30% PEG300 in 0.9% sterile saline 123 I-MAPi were injected and the mice imaged 1 h post injection.
Hematoxylin-Eosin (H&E) staining
Brains were collected from mice at the time of death. The collected brains were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, CA), flash-frozen in liquid nitrogen and cut into 10 μm sections using a Vibratome UltraPro 5000 Cryostat (Vibratome, St. Louis, Quantification of PARPi-FL uptake in the nucleus and cytoplasm of tumor and liver tissue.
Figures and Tables
Tumor control was performed by IV injection of blocking Olaparib dose. Liver control was performed by injection of vehicle. Nuclear vs cytoplasmic uptake was automatically detected using an ImageJ script to detect colocalization of Hoechst (IV injected 5 minutes before extracting the organs) and PARPi-FL. Student t-test, **p-value < 0.01, ***p-value < 0.001. 
